je.st
news
UPDATE 1-Vertex cystic fibrosis combo succeeds in key late-stage trials
2014-06-25 09:50:35| Biotech - Topix.net
A combination of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco and its experimental lumacaftor succeeded in improving lung function in a pair of closely watched late-stage trials of patients with the most common genetic mutation associated with the rare lung disease.
Tags: key
update
combo
trials
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||